Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study

溃疡性结肠炎 医学 内科学 选择(遗传算法) 结肠炎 胃肠病学 计算机科学 人工智能 疾病
作者
Edward V Loftus,Séverine Vermeire,Brian G Feagan,Franck-Olivier Le Brun,Alessandra Oortwijn,Ulrik Moerch,William J Sandborn,Toshifumi Hibi
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
标识
DOI:10.1093/ecco-jcc/jjac122
摘要

Abstract Background and Aims Corticosteroid-free remission is an important treatment goal for patients with ulcerative colitis [UC]. The corticosteroid-sparing effects of filgotinib, an oral, Janus kinase 1 preferential inhibitor, were assessed in SELECTION, a placebo-controlled, phase 2b/3 trial in moderately to severely active UC. Methods These post hoc analyses assessed 1-, 3-, 6-, and 8-month rates of corticosteroid-free clinical remission at Week 58 and change in median daily prednisone-equivalent dose over time. A matching-adjusted indirect comparison [MAIC] of maintenance studies assessed corticosteroid-free remission with filgotinib 200 mg, intravenous vedolizumab, subcutaneous vedolizumab, and oral tofacitinib. Results The Maintenance Study full analysis set included 199 patients receiving filgotinib 200 mg and 98 receiving placebo. Among patients receiving corticosteroids at Maintenance Study baseline, at Week 58, 30.4%, 29.3%, 27.2%, and 21.7% receiving filgotinib had been in corticosteroid-free remission for ≥1, ≥3, ≥6, or ≥8 months, respectively, versus 6.4% receiving placebo across thresholds [p <0.05]. Median daily prednisone-equivalent dose decreased from 17.5 mg/day to 10.0 mg/day with filgotinib treatment during the Maintenance Study. Based upon the MAIC, filgotinib was associated with greater likelihood of corticosteroid-free clinical remission versus intravenous vedolizumab (odds ratio [OR], 15.2; 95% confidence interval [CI], 1.6–139.9; p <0.05]) and similar odds to subcutaneous vedolizumab [OR, 3.8; CI, 0.2–63.8; p = 0.36] in biologic-naïve patients, and similar odds to tofacitinib overall [OR, 2.0; 0.4–9.1; p = 0.39]. Conclusions Filgotinib 200 mg demonstrated corticosteroid-sparing effects and maintained corticosteroid-free clinical remission in patients with UC. MAIC results should be interpreted cautiously given the large CIs and differences in study design and patient populations. [ClinicalTrials.gov: NCT02914522].

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一区的王完成签到 ,获得积分10
刚刚
搬砖的化学男完成签到 ,获得积分0
1秒前
满意的迎南完成签到 ,获得积分10
1秒前
wang完成签到,获得积分10
1秒前
Lynn完成签到 ,获得积分10
7秒前
踏实的无敌完成签到,获得积分10
9秒前
10秒前
星辰大海应助淡然的熊猫采纳,获得10
17秒前
piaoaxi完成签到 ,获得积分10
18秒前
mol完成签到 ,获得积分10
18秒前
19秒前
烊烊完成签到,获得积分10
22秒前
yang杨完成签到,获得积分10
22秒前
thuuu完成签到,获得积分10
24秒前
INBI发布了新的文献求助30
24秒前
Catherkk完成签到,获得积分10
24秒前
粱乘风完成签到,获得积分10
24秒前
Belinda完成签到 ,获得积分10
25秒前
AN完成签到,获得积分10
26秒前
myg123完成签到 ,获得积分10
28秒前
Seth完成签到,获得积分10
29秒前
29秒前
神勇友灵完成签到,获得积分10
29秒前
WL完成签到 ,获得积分10
33秒前
35秒前
qcl完成签到,获得积分10
39秒前
41秒前
淡然的熊猫完成签到,获得积分10
41秒前
顺心的安珊完成签到 ,获得积分10
42秒前
43秒前
vsvsgo发布了新的文献求助10
43秒前
负责的白风完成签到,获得积分10
44秒前
shy完成签到,获得积分10
45秒前
life完成签到,获得积分10
46秒前
夏姬宁静完成签到,获得积分10
47秒前
高兴的凝蝶完成签到,获得积分10
48秒前
阿鑫完成签到 ,获得积分10
48秒前
CipherSage应助毅诚菌采纳,获得10
48秒前
xuzj应助科研通管家采纳,获得10
48秒前
48秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022